IKZF1 and systemic lupus erythematosus: CC-220 (iberdomide) is a modulator of the cullin ring ligase 4-cereblon (CRL4CRBN) E3 ubiquitin ligase complex, which induces ubiquitination of the CRBN substrates Aiolos and Ikaros, resulting in their proteasomal degradation.In vitro studies demonstrated that the addition of iberdomide to B cells or PBMCs from SLE patients or healthy subjects, respectively, reduced Aiolos and Ikaros expression and inhibited BAFF-induced B cell differentiation and the production of anti-dsDNA antibodies and anti-phospholipid antibodies56,57.